Clinical trials: Renal Cell Cancer Metastatic
Melanoma, Renal Cell Carcinoma
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
- Conditions
- Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced
- Trial name
- NCT04955743
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma
Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
This study is design to prospectively investigate the safety and efficacy of Toripalimab combined with Axitinib in downsizing tumors in patients with nonmetastatic biopsy-proven clear cell renal cell carcinoma.
- Trial name
- NCT04118855
- Testing
- Toripalimab, Axitinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft…
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03071328
- Testing
- Isovue-M 200
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Metastatic Renal Cell Cancer
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced kidney cancer.
- Trial name
- NCT02843607
- Testing
- Cryosurgery, NK immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Metastatic Cancer, Recurrent Cancer
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors.
- Conditions
- Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma
- Trial name
- NCT03758781
- Testing
- IRX 2, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Kidney Cancer
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00039052
- Testing
- interleukin-4 PE38KDEL cytotoxin
- Where
- 2 sites in United States
- Sponsor
- Neurocrine Biosciences
Metastatic Renal Cell Cancer
A Phase 1b Trial in Patients With Renal Cell Cancer
The purpose of this study is to determine a safe dose of LY573636-sodium to be given in combination with sunitinib to patients with metastatic Renal Cell Carcinoma (RCC) and to determine any side effects that may be associated…
- Trial name
- NCT01258348
- Testing
- Drug: LY573636-sodium, Sunitinib
- Where
- 5 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
Recurrent Melanoma, Recurrent Renal Cell Cancer
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of temsirolimus when given together with bryostatin 1 in treating patients with unresectable or metastatic solid tumors.
- Conditions
- Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage IV Melanoma, Stage IV Renal Cell Cancer
- Trial name
- NCT00112476
- Testing
- bryostatin 1, temsirolimus
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Renal Cell Carcinoma
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
- Trial name
- NCT00975806
- Testing
- Lenalidomide, Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Metastatic Renal Cell Carcinoma
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.
- Trial name
- NCT04076787
- Testing
- Sunitinib
- Where
- Canada
- Volunteers
- 1,769 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma, RCC
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
This is a Phase I/II trial of the combination pegylated IFN-alpha 2b with ixazomib in metastatic renal cell carcinoma (mRCC). Researchers believe that by disabling the protein complex NF-kB, which controls the transfer of genetic…
- Trial name
- NCT02447887
- Testing
- Ixazomib, Pegylated IFN-alpha 2b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Kidney Neoplasms
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
- Trial name
- NCT00678392
- Testing
- Axitinib (AG-013736), Sorafenib
- Where
- 294 sites in United States, Australia and 20 more
- Volunteers
- 723 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
MEtatastic Renal Carcinoma LINes
The hypothesis of this study are as follows: Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
- Trial name
- MERLIN (NCT03928964)
- Where
- 8 sites in France
- Volunteers
- 440 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
This phase I trial studies how well tacrolimus, nivolumab, and ipilimumab work in treating kidney transplant recipients with cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT03816332
- Testing
- Ipilimumab, Nivolumab, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Solid Carcinoma
Imaging of Solid Tumors Using 18F-TRX
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan.
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06942104
- Testing
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rahul Aggarwal
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
pazopanib_NCRCC,Ph2 STUDY
Recent advances in understanding the biology and genetics of renal cell carcinoma (RCC) have led to major therapeutic implications.
- Trial name
- NCT01538238
- Testing
- pazopanib
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Samsung Medical Center
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.